Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
B01 ANTITHROMBOTIC AGENTS
B01A ANTITHROMBOTIC AGENTS
B01AC Platelet aggregation inhibitors excl. heparin
B01AC22 Prasugrel
D05597 Prasugrel hydrochloride (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Blood Products and Modifiers
Platelet Modifying Agents
Adenosine Diphosphate P2Y12 Inhibitors
Prasugrel
D05597 Prasugrel hydrochloride (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
33 Blood and body fluid agents
339 Miscellaneous
3399 Others
D05597 Prasugrel hydrochloride (JAN/USAN)
Drug groups [BR:br08330]
Blood modifier agent
DG01950 Antithrombotic agent
DG01712 Antiplatelet agent
DG01808 Thienopyridine
D05597 Prasugrel hydrochloride
DG01809 P2Y12 receptor antagonist
DG01808 Thienopyridine
D05597 Prasugrel hydrochloride
Metabolizing enzyme substrate
DG02919 CYP2B6 substrate
D05597 Prasugrel hydrochloride
DG01633 CYP3A/CYP3A4 substrate
D05597 Prasugrel hydrochloride
Metabolizing enzyme inhibitor
DG02892 CYP2B6 inhibitor
D05597 Prasugrel hydrochloride
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Purine / pyrimidine
P2RY12
D05597 Prasugrel hydrochloride (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D05597
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D05597
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D05597
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D05597
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D05597
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D05597